The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Osqay denosumab BiosimilarAdditional monitoring | Theramex Ireland Limited | Bone Resorption | 🇪🇺 EU 2026-01-08 | Order → |
| Teduglutide Viatris teduglutide Generic | Viatris Limited | Short Bowel Syndrome | 🇪🇺 EU 2026-01-08 | Order → |
| Teizeild teplizumab PRIMEAdditional monitoring | Sanofi Winthrop Industrie | Diabetes Mellitus, Type 1 | 🇪🇺 EU 2026-01-08 | Order → |
| Nereus tradipitant New molecular entity | Vanda Pharms Inc | 🇺🇸 US 2025-12-30 | Order → | |
| Yartemlea narsoplimab-wuug New biologicPriority review | Omeros Corp | 🇺🇸 US 2025-12-23 | Order → | |
| Mucinex 12Hr Cold & Fever Multi-Symptom dextromethorphan hydrobromide, guaifenesin, naproxen sodium New combination | Reckitt Benckiser | 🇺🇸 US 2025-12-22 | Order → | |
| Wayrilz rilzabrutinib OrphanAdditional monitoring | Sanofi B.V. | Purpura, Thrombocytopenic, Idiopathic | 🇪🇺 EU 2025-12-22 | Order → |
| Wegovy semaglutide New dosage form | Novo | 🇺🇸 US 2025-12-22 | Order → | |
| Boncresa denosumab-mobz Biosimilar | Amneal Pharms Llc | 🇺🇸 US 2025-12-19 | Order → | |
| Jascayd nerandomilast New indication (separate NDA)Priority review | Boehringer Ingelheim | 🇺🇸 US 2025-12-19 | Order → | |
| Myqorzo aficamten New molecular entity | Cytokinetics | 🇺🇸 US 2025-12-19 | Order → | |
| Oziltus denosumab-mobz Biosimilar | Amneal Pharms Llc | 🇺🇸 US 2025-12-19 | Order → | |
| Nufymco ranibizumab-leyk Biosimilar | Formycon Ag | 🇺🇸 US 2025-12-18 | Order → | |
| Rybrevant Faspro amivantamab and hyaluronidase-lpuj New biologicPriority review | Janssen Biotech | 🇺🇸 US 2025-12-17 | Order → | |
| Exdensur depemokimab-ulaa New biologic | Glaxosmithkline Llc | 🇺🇸 US 2025-12-16 | Order → | |
| Vybrique sildenafil citrate New dosage form | Ibsa | 🇺🇸 US 2025-12-16 | Order → | |
| Cardamyst etripamil New molecular entity | Milestone Pharms Usa | 🇺🇸 US 2025-12-12 | Order → | |
| Lerochol lerodalcibep-liga New biologic | Lib Therapeutics, Inc. | 🇺🇸 US 2025-12-12 | Order → | |
| Nuzolvence zoliflodacin New molecular entityPriority review | Entasis Therap | 🇺🇸 US 2025-12-12 | Order → | |
| Daybue Stix trofinetide New dosage form | Acadia Pharms Inc | 🇺🇸 US 2025-12-11 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.